GlassScriptPhysician profile
Mohammad S Alsorogi
NPI 1598974123
$111,007.52
in general payments reported to CMS, 2019-2025
31 companies · $9,807 in 2025
The $9,807 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $11K · 2021: $23K · 2022: $5,121 · 2023: $18K · 2024: $9,318 · 2025: $9,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $1,910 · Food and Beverage: $1,399 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,087.50 |
| Travel and Lodging | $1,910.34 |
| Food and Beverage | $1,398.50 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38,422.16 | 2019-2025 | Botox |
| Acorda Therapeutics, INC | $21,275.99 | 2019-2024 | Inbrija |
| Mdd US Operations, LLC | $20,670.00 | 2019-2022 | |
| Biogen, INC. | $14,927.96 | 2019-2021 | |
| Allergan, INC. | $8,355.24 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $1,576.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,549.83 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $1,412.11 | 2019-2020 | |
| Amgen INC. | $568.83 | 2019-2021 | |
| Noctrix Health, INC. | $326.73 | 2025 | Nidra |
| Genentech USA, INC. | $325.63 | 2019-2023 | Ocrevus, Enspryng |
| Alexion Pharmaceuticals, INC. | $262.23 | 2019-2024 | Ultomiris |
| Emd Serono, INC. | $211.69 | 2019-2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $145.47 | 2019-2021 | |
| Celgene Corporation | $118.38 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $107.61 | 2019 | |
| Boston Scientific Corporation | $101.78 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $100.91 | 2022 | |
| Amneal Pharmaceuticals LLC | $94.74 | 2019-2024 | Rytary |
| Ucb, INC. | $91.67 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $67.52 | 2019-2024 | Nuplazid |
| Merz North America, INC. | $56.71 | 2019-2020 | |
| Medtronic USA, INC. | $53.14 | 2019-2020 | |
| Sk Life Science, INC. | $49.82 | 2021 | |
| Adamas Pharmaceuticals, INC. | $30.70 | 2019 | |
| Lundbeck LLC | $26.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $20.96 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.99 | 2021 | |
| Pfizer INC. | $13.25 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.18 | 2019 | |
| Lilly USA, LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alsorogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.